- Home
- BCDA vs PSTV Comparison
BCDA vs PSTV Comparison
Compare BCDA & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- PSTV
- Stock Information
- Founded
- BCDA N/A
- PSTV 1996
- Country
- BCDA United States
- PSTV United States
- Employees
- BCDA N/A
- PSTV N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- BCDA Health Care
- PSTV Health Care
- Exchange
- BCDA Nasdaq
- PSTV Nasdaq
- Market Cap
- BCDA 7.9M
- PSTV 9.4M
- IPO Year
- BCDA N/A
- PSTV N/A
- Fundamental
- Price
- BCDA $2.68
- PSTV $1.40
- Analyst Decision
- BCDA Strong Buy
- PSTV Strong Buy
- Analyst Count
- BCDA 1
- PSTV 2
- Target Price
- BCDA $25.00
- PSTV $14.00
- AVG Volume (30 Days)
- BCDA 73.1K
- PSTV 86.1K
- Earning Date
- BCDA 11-06-2024
- PSTV 10-29-2024
- Dividend Yield
- BCDA N/A
- PSTV N/A
- EPS Growth
- BCDA N/A
- PSTV N/A
- EPS
- BCDA N/A
- PSTV N/A
- Revenue
- BCDA $428,000.00
- PSTV $5,509,000.00
- Revenue This Year
- BCDA $6.92
- PSTV $11.13
- Revenue Next Year
- BCDA N/A
- PSTV N/A
- P/E Ratio
- BCDA N/A
- PSTV N/A
- Revenue Growth
- BCDA 0.71
- PSTV 113.20
- 52 Week Low
- BCDA $1.96
- PSTV $0.97
- 52 Week High
- BCDA $23.25
- PSTV $2.78
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- PSTV 48.32
- Support Level
- BCDA $2.39
- PSTV $1.20
- Resistance Level
- BCDA $2.90
- PSTV $1.45
- Average True Range (ATR)
- BCDA 0.18
- PSTV 0.11
- MACD
- BCDA -0.00
- PSTV 0.01
- Stochastic Oscillator
- BCDA 53.70
- PSTV 66.67
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).